StockData
NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Nuvectis Pharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$18.94+0.34 (+1.83%)

Close on Oct 19, 2026

Market cap
$444.64M
P/E (TTM)
–
Dividend yield
0.00%

Nuvectis Pharma, Inc. revenue by segment

No segment breakdown reported

Nuvectis Pharma does not break out revenue by segment, region or product in the tagged data of its filings for this period type.